Skip to main content
. Author manuscript; available in PMC: 2024 Oct 26.
Published in final edited form as: Cell. 2023 Oct 16;186(22):4757–4772. doi: 10.1016/j.cell.2023.09.023

Figure 4. Amyloid and tau biomarker changes in relation to symptom onset with predicted effects of amyloid and tau targeted therapies in current and planned trials.

Figure 4.

(A) Hypothetical pattern of soluble and insoluble amyloid and tau biomarker changes in relationship to symptom onset based on work from the Dominantly Inherited Alzheimer’s Network (DIAN; Barthelemy et al, 2019) modified from a slide presented at AD/PD2022 by Dr. Randall Bateman. (B) Representation of biomarker and cognitive changes after treatment with lecanemab or donanemab in recent Phase 3 studies. (C) Predicted biomarker changes if current A3–45 (AHEAD) study is positive. (D) Predicted biomarker changes if planned Alzheimer’s Tau Platform (ATP) study is positive. (E) Predicted biomarker changes if a hypothetical “A2” even earlier intervention study to prevent “amyloid positivity” succeeds.